Prix Galien Canada for innovation awarded to first treatment to show
survival benefit for patients with the most deadly form of skin cancer
MONTREAL, Nov. 21, 2013 /CNW/ - Bristol-Myers Squibb Canada is pleased
to announce that YERVOY® (ipilimumab) a novel immuno-oncology therapy for metastatic melanoma
has been awarded the Prix Galien Canada 2013 Innovative Product Award.
This award, presented at a ceremony last night in Montreal, recognizes
the significant impact Yervoy has had in treating this most aggressive
and deadly form of skin cancer.
Yervoy, which has now been approved in more than 40 countries around the
world, was approved by Health Canada in February 2012 as the first and
only treatment for advanced melanoma proven to extend survival in a
phase three trial. Yervoy is indicated for the treatment of
unresectable or metastatic melanoma in patients who have failed or do
not tolerate other systemic therapy for advanced disease.
"We are very proud of the difference Yervoy has made, and will continue
to make, in the lives of Canadians with metastatic melanoma and their
families," said Awny Farajallah, Vice-President, Medical, Bristol-Myers
Squibb Canada. "Yervoy represents the important progress we have made
in immuno-oncology, a rapidly-evolving field of cancer research and
treatment focused on harnessing the power of the body's immune system
to fight cancer."
Unlike traditional therapies that target the tumour, immuno-oncology
agents are designed to harness the natural capabilities of the
patient's immune system to fight cancer by targeting the very same
pathways tumor cells use to evade recognition and destruction. Yervoy
specifically blocks cytotoxic T lymphocyte-associated antigen-4
(CTLA-4), which plays a role in suppressing the normal immune response.
Yervoy blocks that suppression to allow the immune system to respond to
melanoma cancer cells.
Yervoy clinical evidence
In a pivotal randomized phase three clinical study, the median overall
survival was 10 months for Yervoy and six months for the comparator
treatment, a peptide vaccine (gp100). Yervoy has also demonstrated
durable long-term survival in some patients. The Kaplan-Meier estimated
survival rate with Yervoy at both one and two years was almost doubled
when measured against patients treated with gp100, 46 per cent versus
25 per cent at one year and 24 per cent versus 14 per cent at two
years. Data were recently presented at the European Cancer Congress in
Amsterdam in September on long-term survival results from a pooled
analysis of 12 studies of Yervoy at different doses and regimens in
more than 1,800 patients with metastatic or locally advanced or
unresectable melanoma, which showed that approximately 22% of patients
were alive at three years with some followed for up to 10 years.
The types of adverse events (AEs) attributed to Yervoy are generally
related to its mechanism of action, that is, immune-based.
Immune-mediated adverse reactions, sometimes fatal, include
enterocolitis, intestinal perforation, hepatitis, dermatitis,
neuropathy, endocrinopathy as well as toxicity in other organ systems.
Adverse events associated with Yervoy are managed by the administration
of systemic corticosteroids, dose discontinuation and/or the use of
About the Prix Galien Canada
The Prix Galien is the most prestigious award in the field of Canadian
pharmaceutical research and innovation. Referred to as the Nobel Prize
of pharmaceutical research, it recognizes the efforts and achievements
of pharmaceutical research and development. The Prix Galien Canada is a
branch of Innovation Life Canada. www.prix-galien-canada.com.
About Bristol-Myers Squibb Canada
Bristol-Myers Squibb Canada is an indirect wholly-owned subsidiary of
Bristol-Myers Squibb Company, a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines that
help patients prevail over serious diseases. For more information,
please visit www.bmscanada.ca.
YERVOY® is a registered trademark of Bristol-Myers Squibb Company.
SOURCE: Bristol-Myers Squibb Canada
For further information:
Senior Manager, Corporate and Business Communications
Bristol-Myers Squibb Canada